D
uring the past 2 decades, seminal discoveries have identified the genetic basis of important cardiovascular diseases, including hypertrophic and dilated cardiomyopathy (associated with mutations in sarcomere and structural genes), 1 arrhythmogenic cardiomyopathy (associated with mutations in desmosomal genes), 2 inherited arrhythmias (associated with mutations in transmembrane ion channels genes), 3 and Marfan and related syndromes (associated with mutations in genes encoding connective tissue elements). 4 These discoveries have created an important role for genetic testing in the care of families with inherited cardiovascular disease, as reflected in guidelines from numerous professional organizations 5-11 recommending genetic testing to improve the diagnosis and management of patients and at-risk family members. However, many physicians may not believe that they are fully equipped to handle complex genetic results. 12,13 The American Heart Association 14 recently outlined a statement to enhance literacy in cardiovascular genetics for physicians in the genomic era. This primer provides an overview of the role of genetic testing for inherited cardiovascular disease via the following: highlighting practical considerations to successfully integrate genetic testing into clinical management and focusing on the most common tests for inherited cardiovascular diseases, including multigene panel tests for diagnostic testing and single-variant tests for predictive genetic testing to determine which relatives inherited the family's causal variant. The general principles described apply to most adult-onset mendelian disorders: conditions that typically manifest years to decades after birth and are driven by a single gene defect imparting a large effect.
Why Test: Clinical Uses for Genetic Testing
Genetic testing currently is used most frequently in the following situations: 1. Diagnostic testing to identify the underlying genetic etiology in a patient with known or suspected inherited cardiovascular disease. 2. Predictive genetic testing in apparently healthy relatives to determine who has inherited the family's causal variant and is at risk for developing disease.
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In both situations, genetic testing should begin in wellphenotyped individuals, ideally coupled with comprehensive family evaluation to aid in interpreting and applying results.
Diagnostic Genetic Testing
Genetic testing can establish a specific, etiologically based diagnosis. This testing is particularly helpful in situations in which a relatively crude clinical phenotype is shared by multiple conditions (phenocopies), each with a different underlying cause, prognosis, treatment, and implications for family. For example, left ventricular hypertrophy in hypertrophic cardiomyopathy may be difficult to distinguish from athlete's heart, hypertensive heart disease, storage cardiomyopathy (eg, Fabry disease), or infiltrative process (eg, cardiac amyloidosis). Identifying a pathogenic (disease-causing) GLA variant in a patient with left ventricular hypertrophy would confirm a diagnosis of Fabry disease and allow for appropriate management, including screening for noncardiac disease manifestations and consideration of enzyme replacement therapy. Likewise, determining the genetic etiology of thoracic aortic aneurysms, which may be a manifestation of syndromic or nonsyndromic conditions, may lead to different thresholds for prophylactic aortic surgery.
9 Table 1 lists genetic testing available for the most common inherited cardiovascular diseases. In most cases, diagnosis is established phenotypically from clinical cardiovascular testing. However, the presence of a definitively pathogenic variant constitutes a diagnostic criterion for certain conditions, including catecholaminergic polymorphic ventricular tachycardia, Loeys-Dietz syndrome, and Marfan syndrome. Therefore, identification of a pathogenic variant may facilitate a diagnosis in cases in which clinical diagnostic criteria are not completely fulfilled. An important caveat is that genetic testing is probabilistic and may not yield definitively diagnostic results. Results should be correlated with the associated phenotype ideally not just in 1 individual but across the family.
Predictive Genetic Testing and Family Evaluation
For most inherited cardiovascular diseases, the inheritance pattern is autosomal dominant, with a 50% chance of transmission to each offspring regardless of sex. Therefore, evaluation of at-risk healthy family members is recommended. The goals of phenotypic and genotypic family evaluations are to identify individuals with previously unrecognized disease and currently healthy family members who are at risk for future disease development and require longitudinal follow-up. 11 The overall strategy for family screening is summarized in Figure 1 . Phenotypic evaluation starts with first-degree relatives of affected individuals and is repeated periodically because penetrance (the expression of the clinical phenotype associated with the causal variant) for some conditions may be delayed and diagnostic features may not manifest until adulthood. The frequency and components of longitudinal phenotypic evaluation of at-risk relatives are based on consensus opinion and vary depending on the underlying condition. For inherited cardiomyopathies, longitudinal evaluation of at-risk relatives typically consists of, at a minimum, echocardiography and electrocardiography repeated every 1 to 5 years based on age (most frequently during adolescence and young adulthood). Follow-up should be further tailored on the basis of features relevant to individual relatives or families. If a definitively pathogenic variant in the family has been identified, predictive genetic testing can be pursued to identify efficiently which relatives have inherited that variant and which have not. Relatives confirmed to carry the family's variant are at risk for disease development. They should undergo serial phenotypic evaluation and be informed of the risk for transmission to offspring. Relatives who do not carry the family's variant can be reassured and dismissed from longitudinal phenotypic evaluation but instructed to seek attention promptly if any clinical change occurs. 15, 16 Approaches to predictive genetic testing in children vary in different countries. Concerns center on balancing the potential positive and negative psychological effects on the child of determining genotype when the results of testing may not directly change management.
11, 17 Predictive genetic testing can also be used for reproductive planning with prenatal testing during an existing pregnancy to determine whether the fetus inherited the causal variant or through preimplantation genetic diagnosis. Preimplantation genetic diagnosis identifies unaffected embryos, created using in vitro fertilization, for implantation to achieve pregnancy. Predictive testing in the reproductive context is a personal decision that should incorporate consideration of the collective experience of the family as well as the variable penetrance and clinical course associated with most inherited cardiovascular diseases. In cases in which diagnostic genetic testing is not performed or a causal variant was not identified (results were negative or identified variants that were not definitively pathogenic), predictive genetic testing for healthy relatives is not available. Serial phenotypic evaluation becomes the default strategy, typically starting with firstdegree relatives of affected individuals and expanding as new diagnoses are made.
When to Test: Recommendations for Using Genetic Testing
Patients newly diagnosed with an inherited cardiovascular disease should be offered a comprehensive evaluation, including full phenotypic assessment, thorough family history assessment, genetic counseling and testing, and coordinated family evaluation. The Box summarizes the process of incorporating genetic testing into clinical care. Not all scenarios have equivalent likelihood of leading to a diagnostic genetic test result. Therefore, identification of situations that are most likely to yield useful results is important.
High Utility
A definitive diagnosis and familial disease increase the pretest probability of positive genetic test results (identification of a diseasecausing variant). These results can then have a high utility for family members who can benefit from predictive testing. 18, 19 Intermediate Utility
Absence of a family history does not preclude the use of genetic testing. Genetic forms of cardiovascular disease may be present without affected relatives, owing to recessive inheritance, de novo mutations, or reduced penetrance. Genetic testing should still be considered if results would change the patient's management or when at-risk family members would benefit from testing. In this situation, determining with confidence whether a variant is truly the cause of disease without other affected family members to assess segregation may be difficult (Figure 2 ).
Low Utility
In some scenarios, genetic testing is unlikely to be useful (low likelihood of positive genetic test results and a low predicted clinical effect) and should be deferred. One such example is investigating sudden cardiac death in a family in which no living, affected individuals are available for testing and no DNA is available from affected decedents. 20 Initiation of genetic testing in unaffected relatives is unlikely to yield informative results and may provide false reassurance or lead to incorrect diagnoses. 21 Similarly, in situations in which diagnostic genetic testing has identified an ambiguous result, predictive genetic testing of unaffected relatives is not recommended because the variant may not be a reliable marker for disease risk. Obtaining a systematic family history and constructing a detailed pedigreeofatleast3generationsisanimportantpreludeformanagingfami-lies with genetic disease (Box). 22 This information will allow comprehensive assessment of the family's phenotype and identification of relatives who would benefit from predictive testing. When possible, information included on the pedigree should be confirmed by medicalrecordsor,ideally,byprospectivephenotypicevaluationofrelatives. Because multiple genetic variants may be present and act synergistically or as disease modifiers, resulting in more severe disease, genetic testing should ideally begin with the family member who is most severely affected and has the most definitive diagnosis. This approach may be logistically difficult owing to geography and accessibility of the familybutwillmaximizethelikelihoodofidentifyingallvariantsrelevant to the phenotype in the family. Most inherited cardiovascular diseases exhibit genetic heterogeneity, with mutations in multiple genes causing the same condition. Genetic testing for these conditions is accomplished with multigene panels targeted to a specific phenotype, such as hypertrophic cardiomyopathy, or inclusive of a broader array of genes associated with a number of different conditions that may share overlapping features. For example, current comprehensive panels include more than 90 genes implicated in different types of cardiomyopathy. These broader tests may be more efficient and costeffective when an equivocal phenotype in the family includes features of more than 1 condition or in families with overlap syndromes, for example, members of a family with coexisting hypertrophic cardiomyopathy, dilated cardiomyopathy, and left ventricular noncompaction. When the phenotype is unequivocal, selection of a panel that is targeted to that particular condition is preferable because broader panels are unlikely to increase clinical yield and may introduce ambiguous results.
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What the Results Mean: Variant Classification
One of the greatest challenges in multigene panel testing is determining whether an identified sequence variant is the cause of disease. In contrast to traditional laboratory testing, genetic testing is probabilistic in nature 26 and classifies variants along a continuum that reflects the estimated likelihood that a variant causes disease based on the weight of current evidence. Large-scale populationsequencing efforts have highlighted the complexity of the human genome and the remarkable diversity of human genetic variation. Historically, rare sequence variants without other supporting evidence may have been presumed to be pathogenic. However, insights gained from population-sequencing efforts have led to the realization that many benign variants are also rare, prompting a more conservative approach to variant interpretation. 24 The sequencing data from individuals across diverse ancestries, aid in distinguishing rare, pathogenic variants from benign variants that may be enriched in specific ethnic or racial backgrounds. Pathogenic and likely pathogenic variants are generally considered to be positive results, meaning that they provide the genetic etiology for disease ( Table 2) . These results may be considered for clinical decision making, including predictive genetic testing. Given the lesser amount of supporting evidence available for likely pathogenic variants, caution is warranted when using these results for predictive genetic testing and the subsequent dismissal of genotypenegative relatives from care. In contrast, likely benign and benign variants are generally considered to be negative results, meaning that they do not provide a genetic etiology for disease.
Variants of uncertain significance are considered to be indeterminate results that should not be used for clinical decision making. A variant of uncertain significance does not provide a definitive genetic etiology of disease and should not be used to determine risk for disease in unaffected relatives. However, testing affected relatives to determine whether the variant segregates with disease in the family can provide valuable evidence to support or dismiss variant pathogenicity (Figure 2 ). Segregation analysis involves determining whether the genetic variant in question is consistently associated with clinical disease in a family. Because the appearance of appropriate segregation can occur by chance (eg, a child has a 50% likelihood of inheriting any particular allele from their parent), data from a large number of affected relatives or distantly related af- To use genetic testing responsibly, clinicians should be aware of the complex, dynamic, and sometimes inconsistent nature of variant interpretation and use the support of genetic testing laboratories and publicly available resources such as ClinVar, ClinGen, and the Exome Aggregation Consortium. Of most importance, genetic data must be integrated with the patient's findings and family history to determine the likelihood that a variant is the cause of disease (Box).
How to Order Genetic Testing and Important Considerations
Pretest and posttest genetic counseling are important steps in the genetic testing process. Such counseling is typically provided by the ordering physician or genetic counselors, specially trained clinicians who facilitate decision making about genetic testing and discuss implications of the results for the patient and family. Pretest counseling provides the information necessary for proper informed consent, including the anticipated yield of testing, the probabilistic nature of genetic testing, how the result will affect the patient's medical management, implications for family members, and the potential for reclassification (Box). 26 Pretest genetic counseling also gives the opportunity to explore potential adverse psychosocial sequela that can result from genetic testing, particularly with predictive genetic testing of children for diseases that typically manifest in adulthood. Many of the logistical considerations of genetic testing have improved. Turnaround times are decreasing, with results often available in weeks instead of months. Genetic testing laboratories are increasingly accepting different sample types as sources of DNA, including blood, buccal swabs, and saliva. Coverage by third-party payers, including Medicare and Medicaid, varies state by state across the United States. Internationally, national health care systems often provide coverage for genetic testing (eg, Canada, Italy, France, and the Netherlands); however, this is not universally true (eg, Australia). Nonetheless, costs are decreasing, and many laboratories offer financial assistance programs to contain costs to patients.
The concern about the potential for genetic discrimination for those pursuing predictive genetic testing has previously been identified as a disincentive. 32 Now, federal laws in many countries are designed to provide protections against genetic discrimination by health insurance companies and employers, such as the Genetic Information Nondiscrimination Act of 2008 in the United States. 33 Although the same legal protection does not exist for life insurance or long-term care insurance in the United States, protections may exist in other countries. Therefore, individuals should be informed of relevant discrimination risks to evaluate their current insurance coverage before proceeding with testing.
Family Communication
Caring for individuals with inherited disease involves addressing the family as a unit, a particular consideration for genetic testing. For relatives to access genetic testing, a clear and accurate message must be relayed to them. Privacy laws prevent clinicians from directly contacting family members except in cases of imminent danger; therefore, family outreach must be initiated by the patient. When considering the potential for poor psychosocial functioning owing to the challenges of a diagnosis, 34, 35 considerable barriers to effective communication of genetic information may exist. 36 Facilitation of this communication is the responsibility of the clinical team ordering genetic testing 37 and may involve the provision of materials written by the clinician that explain the results and recommendations for family members in lay terms (ie, a "family letter"). Development of more innovative solutions to improve family communication may increase the uptake of family screening and genetic testing.
Future Directions: Whole Exome and Genome Sequencing
Broader testing platforms, including whole-exome and whole-genome sequencing, are becoming increasingly available and affordable and may play a larger role in clinical care and biomedical investigation. These tests offer the possibility of discovering new disease genes, thereby providing new insights into disease mechanisms and causal pathways. However, owing to the abundance of genetic variation within an individual genome, the chances for discovery are best when broad genetic testing is coupled with comprehensive phenotypic evaluation of multiple affected relatives or patient-parent trios to aid in distinguishing potential causal variants from background genetic variation that is not clinically significant. The yield of novel gene discovery is unknown; therefore, this opportunity must be balanced against the potential of uncovering genetic information that is unrelated to the indication for testing. The ACMG recommended reporting incidentally identified pathogenic variants in 59 genes considered to be medically actionable. 38, 39 Secondary or incidental findings, such as a risk for breast cancer, present challenges to the informed consent process and may lead to additional phenotypic evaluations to understand the implications of the findings. 40 Furthermore, the ACMG list includes genes for inherited cardiac conditions, leading to possible referral of patients to cardiologists for evaluation of these cardiac-related incidental genetic findings. Thus, collaboration with centers with specific expertise in cardiovascular genetics should be strongly considered to help achieve the best outcomes for patients and families.
Conclusions
Genetic testing is a powerful tool in the diagnosis of inherited cardiovascular diseases and identification of at-risk healthy relatives. Owing to constantly increasing availability, cardiologists are now required to befamiliarwiththemyriadofcomplexitiesandimplicationsforpatients and families. When integrated effectively into clinical practice, genetic testing is an essential step toward individualized medicine and, ultimately, effective prevention of cardiovascular disease.
